(763) 302-4100

Patient Portal

|

Pay Your Bill

|

COVID-19 Update

Minneapolis Clinic of Neurology

Contact Us

TEVA48125-CNS-300049:  A multicenter, randomized, Double Blind, placebo controlled,  parallel-group study comparing the efficacy and safety of 2 dose regiments of subcutaneous administration of TEVA-48125 versus placebo for the preventive treatment of chronic migraine.

Sponsor: Teva Pharmaceutical Industries

Phase of Development: Phase III

Study Duration: 16 weeks

 Enrollment Status: Closed                                                                   

TEVA48125-CNS-300050:  A multicenter, randomized, Double Blind, placebo controlled,  parallel-group study comparing the efficacy and safety of 2 dose regiments of subcutaneous administration of TEVA-48125 versus placebo for the preventive treatment of episodic migraine.

Sponsor: Teva Pharmaceutical Industries

Phase of Development: Phase III

Study Duration: 16 weeks

Enrollment Status:   Closed

TEVA48125-CNS-30051:  A multicenter, randomized, double-blind, parallel-group study evaluating the long term safety, tolerability and efficacy of subcutaneous administration of TEVA-48125 for the preventive treatment of migraine.

Sponsor: Teva Pharmaceutical Industries

Phase of Development: Phase III

Study Duration: This is an 18 month rollover study from TEVA48125-CNS-300049 and TEVA48125-CNS-300050 

Enrollment Status:   Closed

UBR-MD-02:  A multicenter, randomized, double blind, placebo controlled, single attack study to evaluate the efficacy, safety and tolerability of oral Ubrogepant in the acute treatment of migraine.

Sponsor: Allergan

Phase of Development: Phase III

Study Duration: Up to 14 days for the screening period prior to randomization, a 60-day period which to treat a single migraine attack, and a 4-week follow up period. (This study can last 1.5-4 months based on the treatment of a single migraine attack).

Enrollment Status: Closed

UBR-MD-04:  A multicenter, randomized, open-label extension study to evaluate the long-term safety and tolerability of oral Ubrogepant in the acute treatment of migraine with or without aura.

Sponsor: Allergan

Phase of Development: Phase III

Study Duration: This is a 52 week rollover study from UBR-MD-01 and UBR-MD-02

Enrollment Status:   Closed

Principal Investigator for the above clinical trials: Jessica Heiring, MD

Research Contact:  763-302-4099

Call Now
Clinic Locations

COVID-19 Update

Minneapolis Clinic of Neurology is remaining open in order to be available to you for your neurology needs. During the recommended social distancing due to COVID-19, in addition to office visits, we are offering telemedicine appointments by video for patients that would like to be seen from the safety of their home.

We continue to provide emergency neurological care at all of the hospitals that we serve, including Mercy Hospital, Unity Hospital, North Memorial Health Hospital, Maple Grove Hospital, Fairview Southdale Hospital, and Fairview Ridges Hospital.

For your safety, services that can wait without harm to your health will be postponed until a later date.  Necessary neurological services that require coming into one of our clinics are still available and will be determined by your neurologic care provider.   If you have a question regarding a currently scheduled appointment please call our office or send a message through our portal.

Burnsville:   952-435-8516
Coon Rapids:   763-427-8320
Edina:   952-920-7200
Golden Valley:   763-588-0661
Maple Grove:   763-302-4114

A mask must be worn by all patients/visitors the entire time while in our office.  Please bring your own personal mask, if available.  No visitors are allowed with patients at this time, with the exception of the following:
     Adults: One healthy adult if assistance to the patient is required.
     Pediatrics: One legal guardian only.

Appointments may be canceled with very short notice should a patient test positive for, or experience signs or symptoms of, COVID-19, our health care capacity change or COVID-19 caseloads in the community increase.

For our patients with Multiple Sclerosis or other Neuro-immunology conditions who may be on medications that may alter your immune system, please follow this link.